title: Interleukin 2 suppression of a murine bladder cancer implanted into kidney, bladder and skin; its organ specificity.
abstract: Little is known about organ associated tumor response to systemic interleukin 2 (IL2) therapy. The effect of IL2 on bladder cancer growth in the skin and in the genitourinary tract was investigated. C3H mice were implanted with the syngeneic transitional cell carcinoma, MBT-2, intradermally (i.d.), beneath the left renal subcapsular area, and in one experiment, simultaneously in the bladder. IL2 (human recombinant form; Biogen Research Co) was given i.p. at 5000 U thrice daily for 5 consecutive days commencing on Day 3, or for 10 to 11 days commencing on Day 10 with some doses omitted at signs of toxicity. For comparison, mice bearing 3-d and 10-d tumors in the skin and subcapsular kidney were treated with chemotherapy (cisplatin, 6 mg./kg. X 3; mitomycin C, 3 mg./kg. X 3; cyclophosphamide, 75 mg./kg. X 1). IL2 therapy mediated growth suppression of 10-d tumors in the genitourinary organs and skin at a similar rate. In contrast to IL2, systemic chemotherapy mediated tumor suppression in an organ specific manner; renal subcapsular tumors responded to the chemotherapy, whereas i.d. tumors were insensitive. Three-day tumors (both i.d. and renal subcapsular tumor) responded relatively well to each treatment compared to 10-d tumors. These data suggest that in systemic immunotherapy with IL2, anatomic location of the tumor is less important for inducing an antitumor response than in chemotherapy.
authors.affiliation: Department of Urology, University of Rochester School of Medicine, New York.
authors.forename: K E
authors.initials: KE
authors.lastname: Lee
authors.forename: R W
authors.initials: RW
authors.lastname: O'Donnell
authors.forename: G H
authors.initials: GH
authors.lastname: Weiss
authors.forename: A T
authors.initials: AT
authors.lastname: Cockett
mesh_terms: D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D007376:Interleukin-2 / Q000494:pharmacology* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D051379:Mice; D008809:Mice, Inbred C3H; D008937:Mitomycins / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D009928:Organ Specificity / Q000187:drug effects; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy
chemical_list: D007376:Interleukin-2; D008937:Mitomycins; D003520:Cyclophosphamide; D002945:Cisplatin